These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
157 related articles for article (PubMed ID: 22101282)
41. Coadministration of sorafenib with rottlerin potently inhibits cell proliferation and migration in human malignant glioma cells. Jane EP; Premkumar DR; Pollack IF J Pharmacol Exp Ther; 2006 Dec; 319(3):1070-80. PubMed ID: 16959960 [TBL] [Abstract][Full Text] [Related]
42. Essential role of TRPC6 channels in G2/M phase transition and development of human glioma. Ding X; He Z; Zhou K; Cheng J; Yao H; Lu D; Cai R; Jin Y; Dong B; Xu Y; Wang Y J Natl Cancer Inst; 2010 Jul; 102(14):1052-68. PubMed ID: 20554944 [TBL] [Abstract][Full Text] [Related]
43. Chemical insights in the concept of hybrid drugs: the antitumor effect of nitric oxide-donating aspirin involves a quinone methide but not nitric oxide nor aspirin. Hulsman N; Medema JP; Bos C; Jongejan A; Leurs R; Smit MJ; de Esch IJ; Richel D; Wijtmans M J Med Chem; 2007 May; 50(10):2424-31. PubMed ID: 17441704 [TBL] [Abstract][Full Text] [Related]
44. Targeting malignant glioma survival signalling to improve clinical outcomes. Wong ML; Kaye AH; Hovens CM J Clin Neurosci; 2007 Apr; 14(4):301-8. PubMed ID: 17276069 [TBL] [Abstract][Full Text] [Related]
45. Diazeniumdiolation of protamine sulfate reverses mitogenic effects on smooth muscle cells and fibroblasts. van Lith R; Yang J; Ameer GA Free Radic Biol Med; 2015 May; 82():13-21. PubMed ID: 25656996 [TBL] [Abstract][Full Text] [Related]
46. Enhancement of anti-tumor activity by low-dose combination of the recombinant urokinase kringle domain and celecoxib in a glioma model. Kim CK; Joe YA; Lee SK; Kim EK; O E; Kim HK; Oh BJ; Hong SH; Hong YK Cancer Lett; 2010 Feb; 288(2):251-60. PubMed ID: 19664879 [TBL] [Abstract][Full Text] [Related]
47. Nitric oxide and BCNU chemoresistance in C6 glioma cells: role of S-nitrosoglutathione. Yang DI; Yin JH; Ju TC; Chen LS; Hsu CY Free Radic Biol Med; 2004 May; 36(10):1317-28. PubMed ID: 15110396 [TBL] [Abstract][Full Text] [Related]
48. Nitric oxide photorelease from a trinuclear ruthenium nitrosyl complex and its in vitro cytotoxicity against melanoma cells. Carneiro ZA; Biazzotto JC; Alexiou AD; Nikolaou S J Inorg Biochem; 2014 May; 134():36-8. PubMed ID: 24522147 [TBL] [Abstract][Full Text] [Related]
49. Suppression of Rac activity induces apoptosis of human glioma cells but not normal human astrocytes. Senger DL; Tudan C; Guiot MC; Mazzoni IE; Molenkamp G; LeBlanc R; Antel J; Olivier A; Snipes GJ; Kaplan DR Cancer Res; 2002 Apr; 62(7):2131-40. PubMed ID: 11929835 [TBL] [Abstract][Full Text] [Related]
50. Cyclic RGD conjugated poly(ethylene glycol)-co-poly(lactic acid) micelle enhances paclitaxel anti-glioblastoma effect. Zhan C; Gu B; Xie C; Li J; Liu Y; Lu W J Control Release; 2010 Apr; 143(1):136-42. PubMed ID: 20056123 [TBL] [Abstract][Full Text] [Related]
51. The antiangiogenic efficacy of NGR-modified PEG-DSPE micelles containing paclitaxel (NGR-M-PTX) for the treatment of glioma in rats. Zhao BJ; Ke XY; Huang Y; Chen XM; Zhao X; Zhao BX; Lu WL; Lou JN; Zhang X; Zhang Q J Drug Target; 2011 Jun; 19(5):382-90. PubMed ID: 20677914 [TBL] [Abstract][Full Text] [Related]
52. Nitric oxide donors prevent while the nitric oxide synthase inhibitor L-NAME increases arachidonic acid plus CYP2E1-dependent toxicity. Wu D; Cederbaum A Toxicol Appl Pharmacol; 2006 Oct; 216(2):282-92. PubMed ID: 16938321 [TBL] [Abstract][Full Text] [Related]
53. The NOtizer--a device for the convenient preparation of diazen-1-ium-1,2-diolates. Konter J; El-Din Ali Ahmed Hassan Abuo-Rahma G; El-Emam A; Lehmann J Methods Enzymol; 2005; 396():17-26. PubMed ID: 16291217 [TBL] [Abstract][Full Text] [Related]
54. Fos-related antigen 1 modulates malignant features of glioma cells. Debinski W; Gibo DM Mol Cancer Res; 2005 Apr; 3(4):237-49. PubMed ID: 15831677 [TBL] [Abstract][Full Text] [Related]
55. Functionalized magnetic nanochains with enhanced MR imaging: A novel nanosystem for targeting and inhibition of early glioma. Zhang Y; Huang Z; Wu Z; Yin G; Wang L; Gao F Colloids Surf B Biointerfaces; 2016 Apr; 140():437-445. PubMed ID: 26803007 [TBL] [Abstract][Full Text] [Related]
56. Combined targeting of adenoviruses to integrins and epidermal growth factor receptors increases gene transfer into primary glioma cells and spheroids. Grill J; Van Beusechem VW; Van Der Valk P; Dirven CM; Leonhart A; Pherai DS; Haisma HJ; Pinedo HM; Curiel DT; Gerritsen WR Clin Cancer Res; 2001 Mar; 7(3):641-50. PubMed ID: 11297260 [TBL] [Abstract][Full Text] [Related]
57. NO to cancer: The complex and multifaceted role of nitric oxide and the epigenetic nitric oxide donor, RRx-001. Scicinski J; Oronsky B; Ning S; Knox S; Peehl D; Kim MM; Langecker P; Fanger G Redox Biol; 2015 Dec; 6():1-8. PubMed ID: 26164533 [TBL] [Abstract][Full Text] [Related]
58. Cellular distribution studies of the nitric oxide-generating antineoplastic prodrug O(2) -(2,4-dinitrophenyl)1-((4-ethoxycarbonyl)piperazin-1-yl)diazen-1-ium-1,2-diolate formulated in Pluronic P123 micelles. Kaur I; Terrazas M; Kosak KM; Kern SE; Boucher KM; Shami PJ J Pharm Pharmacol; 2013 Sep; 65(9):1329-36. PubMed ID: 23927471 [TBL] [Abstract][Full Text] [Related]
59. Controlled photochemical release of nitric oxide from O(2)-naphthylmethyl- and O(2)-naphthylallyl-substituted diazeniumdiolates. Bushan KM; Xu H; Ruane PH; D'Sa RA; Pavlos CM; Smith JA; Celius TC; Toscano JP J Am Chem Soc; 2002 Oct; 124(43):12640-1. PubMed ID: 12392393 [TBL] [Abstract][Full Text] [Related]
60. Controlled Delivery of Nitric Oxide for Cancer Therapy. Alimoradi H; Greish K; Gamble AB; Giles GI Pharm Nanotechnol; 2019; 7(4):279-303. PubMed ID: 31595847 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]